BLAINTRAVENOUS, SUBCUTANEOUSINJECTABLE1 Generic Approved
Approved
Oct 2023
Lifecycle
Growth
Competitive Pressure
30/100
Data completeness
4/8 — Partial
WEZLANA (ustekinumab-auub) by Amgen is interleukin-12 antagonists [moa]. Approved for interleukin-12 antagonist [epc]. First approved in 2023.
Drug data last refreshed 19h ago
Mechanism of Action
Interleukin-12 Antagonists
Pharmacologic Class:
Interleukin-12 Antagonist
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Worked on WEZLANA at Amgen? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.